查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1458418

傷口治療生物製品市場評估：依產品、傷口、最終用戶和地區劃分的機會和預測（2017-2031）

Wound Care Biologics Market Assessment, By Product, By Wound, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球傷口護理生物製劑市場規模將從 2023 年的 20.1 億美元成長到 2031 年的 33.1 億美元，預計在 2024-2031 年期間複合年增長率為 6.45%。

糖尿病足潰瘍和燒傷增加：

該市場的成長主要是由於燒傷和糖尿病足潰瘍盛行率的上升而推動的。隨著世界各地糖尿病盛行率的增加，糖尿病足潰瘍是一種越來越常見的併發症。每年，美國有 160 萬人，全世界有 1,860 萬人患有糖尿病足潰瘍。約 1% 的糖尿病患者會截肢，5% 的患者會出現足部潰瘍。近年來，據估計每年有 1-4% 的糖尿病患者出現足部潰瘍。燒傷是一個公共衛生問題，因為燒傷每年導致全球 18 萬人死亡。其中近三分之二的病例發生在非洲和中東，其中大多數發生在低收入和中等收入國家。皮膚替代品和生長因子等先進治療方法是傷口護理生物製劑的一部分，由於它們能夠促進癒合和減少併發症，因此變得越來越受歡迎。由於人們認識的提高以及對創新和高效傷口護理解決方案的需求不斷增長，傷口治療生物製劑被認為是解決燒傷和糖尿病足潰瘍相關問題的關鍵。

交通事故增加：

全球道路事故率不斷上升，這是推動該市場成長的關鍵因素之一。對傷口治療生物製劑的需求是由對快速有效的傷口癒合的不斷增長的需求以及對生物製劑治療的臨床益處的日益瞭解所推動的。生長因子和組織工程產品等先進療法對於加速癒合過程和減少創傷後併發症的可能性至關重要。據估計，每年有 119 萬人死於交通事故。交通事故是 5 至 29 歲兒童和年輕人死亡的主要原因。低收入和中等收入國家佔世界道路交通死亡人數的 92%。

科技的發展：

傷口護理生物製劑的技術進步正在徹底改變傷口護理領域。這種創新方法利用生長因子、幹細胞和細胞激素來刺激組織再生並加速癒合過程。利用組織工程和 3D 列印技術的生物皮膚替代品提供了傳統移植物的卓越替代品，提供了更好的貼合性和功能性。外用製劑受益於奈米技術和緩釋製劑，提高了其在感染控制和傷口癒合方面的有效性。

北美主導全球傷口護理生物製劑市場：

北美在全球傷口護理生物製劑市場上佔據主導地位的原因有很多。該地區擁有完善的醫療基礎設施，可以輕鬆引進和整合先進的醫療技術。此外，糖尿病和血管疾病等慢性病的高盛行率增加了對先進傷口護理解決方案的需求，使生物製劑成為治療方案的重要組成部分。美國和加拿大的監管環境和報銷政策進一步促進了創新傷口治療生物製劑的採用。

該報告調查了全球傷口治療生物製劑市場，並提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構、影響市場成長的因素分析、我們編製了案例研究、競爭格局、概況各大公司等等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章 全球傷口治療生物製劑市場展望

  • 市場規模/預測
  • 依產品
    • 生物皮膚替代品
    • 外用劑
  • 依傷
    • 潰瘍
    • 手術傷口與創傷
    • 燒傷
  • 依最終用戶
    • 醫院/診所
    • 門診手術中心
    • 燒傷治療中心/傷口診所
  • 依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 依公司劃分的市場佔有率

第五章全球傷口治療生物製品市場展望：依地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章 市場測繪

  • 依產品
  • 依傷
  • 依最終用戶
  • 依地區

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

  • 增長動力
  • 成長限制因素（課題與限制）

第九章 監理架構與創新

  • 專利情況
  • 監管審批
  • 創新/新興技術

第十章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析
  • 併購/合資（如適用）
  • SWOT分析（5家參與企業）
  • 專利分析（如果適用）

第11章價格分析

第十二章案例研究

第十三章 主要公司展望

  • Smith & Nephew Plc
  • Integra LifeSciences Corporation
  • Stryker Corporation
  • Organogenesis Inc
  • MixMedx Inc
  • Kerecis Limited
  • Molnlycke Healthcare AB
  • Lynch Biologics
  • Skye Biologics Holdings LLC
  • Marine Polymer Technologies Inc

第十四章 戰略建議

第十五章關於我們公司/免責聲明

Product Code: MX11215

The global wound care biologics market is projected to witness a CAGR of 6.45% during the forecast period 2017-2031, growing from USD 2.01 billion in 2023 to USD 3.31 billion in 2031F. The global wound care biologics market consists of innovative treatments derived from natural sources or synthetic materials that are utilized in wound care procedures. These biologics include skin replacement products and stem cell therapies, which are essential for promoting tissue regeneration and wound healing. Bioengineered dermal substitutes and other biologic skin substitutes promote neovascularization and collagen formation, among other mechanisms that aid in the healing of chronic ulcers. To treat chronic wounds or diabetic foot ulcers with past histories and increased bioburden, topical agents derived from living organisms or cells are being used more often. Since biologic scaffolds form hydrogels that promote collagen synthesis and wound healing, their use in treating chronic non-healing wounds has shown effective results.

Wound care biologics are widely used in the management and treatment of burns, traumatic injuries, and foot ulcers. Anti-infective wound care products have demonstrated effectiveness in treating wounds with infection, such as diabetic foot ulcers. For long-standing foot ulcers or chronic wounds, biologic interventions have been clinically effective. The global wound care biologics market is being driven significantly by the increasing prevalence of burn injuries, traumatic wounds, and foot ulcers. Other factors that are driving the market growth are technological advancements, a growing geriatric population, and an increasing number of road accidents.

For instance, Biologics company Tides Medical announced the launch of a new product in July 2022, Artacent AC, a tri-layer skin graft designed for use in the treatment of complex or difficult-to-treat wounds. Artacent AC is three times stronger and two times thicker than traditional dual-layer products, making it easier to handle and apply to wound sites. To provide physicians with an advanced amniotic skin graft option, Tides developed Artacent AC, which consists of three layers (amnion-chorion-amnion) as opposed to the conventional two (amnion-amnion).

Increasing Prevalence of Diabetic Foot Ulcer and Burn Injuries

The global wound care biologics market is being driven largely due to the rising incidence of burn injuries and diabetic foot ulcers. Diabetic foot ulcers are among the associated complications that are becoming more common as the prevalence of diabetes increases globally. Every year, 1.6 million Americans and 18.6 million people worldwide suffer from diabetic foot ulcers. About 1% of diabetic patients have their feet amputated, and 5% of patients develop foot ulcers. Over the past few years, it has been estimated that 1-4% of diabetic patients develop foot ulcers each year. Burns are a public health concern since they are responsible for 180,000 deaths globally each year. Almost two-thirds of these are found in the African and South-East Asian regions, with the majority occurring in low- and middle-income countries. Advanced therapies such as skin substitutes and growth factors, which are a part of wound care biologics, are becoming more and more popular for their ability to boost healing and reduce complications. As a result of this increased awareness and the growing need for innovative and efficient wound care solutions, the market for wound care biologics has been positioned as essential to solving the problems associated with burn injuries and diabetic foot ulcers.

Growing Number of Road Accidents

Global traffic accident rates are rising, which is one of the key factors propelling the global wound care biologics market growth. Road accidents frequently cause a range of injuries, from small cuts to severe wounds, necessitating the use of cutting-edge wound care techniques. Demand for wound care biologics is being driven by the growing need for quick and efficient wound healing as well as a greater understanding of the clinical benefits of biologic-based treatments. Advanced therapies, such as growth factors and tissue-engineered products, are essential for accelerating the healing process and reducing the likelihood of complications following traumatic injuries. An estimated 1.19 million people lose their lives in traffic-related incidents each year. For kids and young adults aged 5 to 29, traffic accidents are the main cause of death. Despite having about 60% of the world's vehicles, low- and middle-income countries account for 92% of all road fatalities worldwide.

Technological Advancements

Technological advancements in the global wound care biologics market are revolutionizing the landscape of wound care management. Innovative approaches involve the utilization of growth factors, stem cells, and cytokines to stimulate tissue regeneration and accelerate the healing process. Biological skin substitutes, leveraging tissue engineering and 3D printing technologies, are providing better alternatives to traditional grafts, offering improved compatibility and functionality. Topical agents are benefiting from nanotechnology and sustained release formulations, improving their efficacy in infection control and wound healing.

For instance, in January 2023, Kerecis introduced its GraftGuide fish-skin product line, which addresses the difficulties associated with burn healing. GraftGuide Mano is made to adapt to the shape of a hand. Surgeons do not need to customize the graft because the product can easily cover the three-dimensional structure of the hand. This reduces the surgical time and eliminates the need for numerous grafts and bulky fixation.

Dominance of Hospitals

Due to the complex nature of the hospital environment, wound care is mostly used in hospitals as compared to ambulatory surgical centers and burn care centers. Wounds of varying degrees of severity are more common in hospitals because they typically handle a wide variety of medical cases, including complicated surgeries, trauma, and chronic conditions. Hospitals are equipped with a comprehensive infrastructure that facilitates access to a wide range of wound care resources, advanced diagnostic tools, and specialized medical professionals. Hospitals are the main hub for comprehensive wound care management because they are equipped to handle acute cases that may need intensive care and continuous monitoring. This allows medical professionals to address a wide range of wounds, from severe injuries to post-surgical incisions.

North America Dominates the Global Wound Care Biologics Market

North America's dominance in the global wound care biologics market is being driven by various factors. The region has a well-established healthcare infrastructure that readily adopts and integrates advanced medical technologies. In addition, a high prevalence of chronic conditions such as diabetes and vascular diseases, has led to an increased demand for advanced wound care solutions, positioning biologics as a critical component for treatment protocols. The regulatory environment and reimbursement policies in the United States and Canada further facilitate the widespread adoption of innovative wound care biologics.

In October 2023, MTF Biologics announced that the FDA granted an IDE (Investigational Device Exemption) to initiate a clinical study verifying the efficacy and safety of FlexHD Pliable for breast reconstruction based on implants. This is the first IDE approval for a human acellular dermal matrix for breast reconstruction granted by the FDA.

Future Market Scenario (2024-2031F)

Allografts and xenografts are increasingly being used as skin substitutes beyond just dressings, indicating a shift towards more advanced biologic skin substitutes.

Bioengineered skin substitutes are gaining prominence as an alternative approach to treating large skin defects caused by burns or trauma. These substitutes can be classified based on their chemical composition, scaffold material, and skin components.

Incorporating functional moieties into skin substitutes is a growing trend. For instance, antimicrobials and wound healing agents are being integrated into bioengineered smart skin substitutes. These functionalized substitutes aim to enhance wound healing outcomes and prevent infections.

Key Players Landscape and Outlook

The global wound care biologics market is characterized by a competitive landscape with key players driving innovation and market expansion. These market players are investing in R&D to improve product efficacy, patient comfort, and dosage precision. Partnerships and collaborations between medical device and pharmaceutical companies are being formed with the aim of the development of advanced wound care products that can be integrated with smartphones and applications.

For instance, in May 2023, the Acellular dermal matrix, a natural soft tissue reconstruction solution that AlloSource announced to provide long-term structural support, AlloMend Duo ADM was developed to assist surgeons in reconstructing soft tissue defects. A scaffold for cell repopulation and natural host tissue regeneration is provided by the deep reticular dermal allograft, which blends in with the surrounding tissue.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Wound Care Biologics Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Product
    • 4.2.1. Biological Skin Substitutes
    • 4.2.2. Topical Agents
  • 4.3.By Wound
    • 4.3.1. Ulcers
    • 4.3.2. Surgical & Traumatic Wounds
    • 4.3.3. Burns
  • 4.4.By End-user
    • 4.4.1. Hospitals & Clinics
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Burn Care Centers & Wound Clinic
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Wound Care Biologics Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Product
      • 5.1.2.1.Biological Skin Substitutes
      • 5.1.2.2.Topical Agents
    • 5.1.3.By Wound
      • 5.1.3.1.Ulcers
      • 5.1.3.2.Surgical & Traumatic Wounds
      • 5.1.3.3.Burns
    • 5.1.4.By End-user
      • 5.1.4.1.Hospitals & Clinics
      • 5.1.4.2.Ambulatory Surgical Centers
      • 5.1.4.3.Burn Care Centers & Wound Clinic
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Product
      • 5.1.5.2.1.Biological Skin Substitutes
      • 5.1.5.2.2.Topical Agents
      • 5.1.5.3.By Wound
      • 5.1.5.3.1.Ulcers
      • 5.1.5.3.2.Surgical & Traumatic Wounds
      • 5.1.5.3.3.Burns
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospitals & Clinics
      • 5.1.5.4.2.Ambulatory Surgical Centers
      • 5.1.5.4.3.Burn Care Centers & Wound Clinic
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3.Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4.South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5.Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. U.A.E.
    • 5.5.3. South Africa

6.Market Mapping, 2023

  • 6.1.By Product
  • 6.2.By Wound
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Smith & Nephew Plc
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Integra LifeSciences Corporation
  • 13.3.Stryker Corporation
  • 13.4.Organogenesis Inc
  • 13.5.MixMedx Inc
  • 13.6.Kerecis Limited
  • 13.7.Molnlycke Healthcare AB
  • 13.8.Lynch Biologics
  • 13.9.Skye Biologics Holdings LLC
  • 13.10.Marine Polymer Technologies Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 3.Global Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 4.Global Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 5.Global Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Wound Care Biologics Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 9.North America Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 10.North America Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 11.North America Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 15.United States Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 16.United States Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 17.United States Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 20.Canada Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 21.Canada Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 22.Canada Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 25.Mexico Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 26.Mexico Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 27.Mexico Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 30.Europe Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 31.Europe Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 32.Europe Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 36.Germany Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 37.Germany Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 38.Germany Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 41.France Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 42.France Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 43.France Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 46.Italy Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 47.Italy Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 48.Italy Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 51.United Kingdom Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 52.United Kingdom Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 53.United Kingdom Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 56.Russia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 57.Russia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 58.Russia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 61.Netherlands Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 62.Netherlands Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 63.Netherlands Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 66.Spain Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 67.Spain Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 68.Spain Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 71.Turkey Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 72.Turkey Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 73.Turkey Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 76.Poland Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 77.Poland Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 78.Poland Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 81.South America Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 82.South America Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 83.South America Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 87.Brazil Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 88.Brazil Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 89.Brazil Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 92.Argentina Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 93.Argentina Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 94.Argentina Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 97.Asia-Pacific Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 98.Asia-Pacific Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 99.Asia-Pacific Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 101.India Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 103.India Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 104.India Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 105.India Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 108.China Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 109.China Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 110.China Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 113.Japan Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 114.Japan Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 115.Japan Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 118.Australia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 119.Australia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 120.Australia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 123.Vietnam Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 124.Vietnam Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 125.Vietnam Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 128.South Korea Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 129.South Korea Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 130.South Korea Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 133.Indonesia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 134.Indonesia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 135.Indonesia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 138.Philippines Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 139.Philippines Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 140.Philippines Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 143.Middle East & Africa Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 144.Middle East & Africa Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 145.Middle East & Africa Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Wound Care Biologics Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 149.Saudi Arabia Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 150.Saudi Arabia Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 151.Saudi Arabia Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 154.UAE Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 155.UAE Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 156.UAE Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Wound Care Biologics Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Wound Care Biologics Market, By Volume, in Billion Units, 2017-2031F
  • Figure 159.South Africa Wound Care Biologics Market Share (%), By Product, 2017-2031F
  • Figure 160.South Africa Wound Care Biologics Market Share (%), By Wound, 2017-2031F
  • Figure 161.South Africa Wound Care Biologics Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Wound Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023